Logo

Sherlock Biosciences: Bryan Dechairo

Jul 12, 2021

Sherlock Biosciences has appointed Bryan Dechairo as president and CEO. He will also join Sherlock’s board of directors. Dechairo succeeds cofounder Rahul Dhanda, who will continue to serve as a board member until the end of 2021, and then as a strategic adviser in 2022. 

Dechairo joins Sherlock from Myriad Genetics, where he served as executive VP of clinical development and oversaw the company's development portfolio. Before joining Myriad, he served as chief medical officer, CSO, and senior VP of research and development at Assurex Health, which was acquired by Myriad in 2016. Prior to Assurex Health, Dechairo held roles of increasing responsibility at Medco Health Solutions, Pfizer, and other diagnostic and therapeutics companies. He also served on the board of directors for the National Alliance on Mental Illness.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.